Danaher Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Danaher wird ein jährliches Gewinn- und Umsatzwachstum von 14.1% bzw. 7.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13% betragen.
Wichtige Informationen
14.1%
Wachstumsrate der Gewinne
14.19%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 18.7% |
| Wachstumsrate der Einnahmen | 7.2% |
| Zukünftige Eigenkapitalrendite | 13.04% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 09 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • Aug 14
Danaher: 2027 Growth Reacceleration Should Drive Upside
Summary Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR’s valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding. Bioprocessing order delays are temporary, with over $100 million in revenue shifting to 2027, positioning DHR for future upside. Read the full article on Seeking Alpha
Narrative-Update • Jul 23
DHR: Bioprocess Recovery And Diagnostics Expansion Will Support Premium Multiple
Danaher’s analyst price target is being reset modestly lower toward about $230, as analysts factor in recent bioprocessing misses, a higher assumed discount rate, and a lower future P/E multiple, even while keeping broadly constructive views on the core life sciences and diagnostics franchises. Analyst Commentary Recent Street research around Danaher highlights a mix of optimism about the long term potential of its life sciences and diagnostics businesses and concern about near term execution, particularly in bioprocessing.Narrative-Update • Jun 26
DHR: Bioprocess Recovery And Masimo Integration Will Support Premium Multiple
Danaher’s analyst price target has been reduced by about $5 to $242, as analysts factor in a slightly higher discount rate, a more conservative profit margin, and updated views on life science tools demand that balance cautious sector sentiment with selective signs of recovery. Analyst Commentary Recent research around Danaher points to a mixed setup, with some analysts focusing on recovery potential in life science tools and bioprocessing, and others highlighting valuation questions and business complexity.Narrative-Update • May 19
DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple
Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.Narrative-Update • May 02
DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple
Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.Narrative-Update • Apr 16
DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple
Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.Narrative-Update • Apr 01
DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple
Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.Narrative-Update • Mar 18
DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple
Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.Narrative-Update • Mar 04
DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple
The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.Narrative-Update • Feb 17
DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple
Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.Narrative-Update • Feb 03
DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook
Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.Narrative-Update • Jan 19
DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple
Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.Narrative-Update • Jan 05
DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple
Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.Narrative-Update • Dec 19
DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers
Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.Narrative-Update • Dec 04
DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty
Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.Narrative-Update • Nov 20
DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside
Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.Narrative-Update • Nov 04
DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds
Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.Narrative-Update • Oct 21
Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher
Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.Narrative-Update • Sep 11
Advanced Diagnostics And Personalized Therapies Will Expand Global Markets
Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.Seeking Alpha • Mar 31
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Mar 22
Danaher: Near 5-Year Low Is A Great Entry Point
Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking AlphaGewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 30,385 | 5,460 | 7,105 | 8,179 | 17 |
| 12/31/2027 | 28,455 | 5,146 | 6,407 | 7,535 | 24 |
| 12/31/2026 | 26,336 | 4,204 | 5,517 | 6,560 | 24 |
| 6/26/2026 | 25,107 | 3,990 | 5,466 | 6,635 | N/A |
| 3/27/2026 | 24,778 | 3,675 | 5,291 | 6,439 | N/A |
| 12/31/2025 | 24,568 | 3,600 | 5,260 | 6,416 | N/A |
| 9/26/2025 | 24,268 | 3,503 | 5,017 | 6,318 | N/A |
| 6/27/2025 | 24,013 | 3,413 | 4,862 | 6,169 | N/A |
| 3/28/2025 | 23,820 | 3,765 | 4,902 | 6,248 | N/A |
| 12/31/2024 | 23,875 | 3,899 | 5,296 | 6,688 | N/A |
| 9/27/2024 | 23,742 | 3,934 | 4,978 | 6,288 | N/A |
| 6/28/2024 | 23,568 | 4,056 | 5,081 | 6,447 | N/A |
| 3/29/2024 | 23,737 | 4,069 | 5,548 | 6,956 | N/A |
| 12/31/2023 | 23,890 | 4,200 | 5,781 | 7,164 | N/A |
| 9/29/2023 | 21,026 | 4,408 | 6,842 | 8,086 | N/A |
| 6/30/2023 | 23,065 | 5,019 | 7,257 | 8,424 | N/A |
| 3/31/2023 | 24,904 | 5,757 | 7,364 | 8,498 | N/A |
| 12/31/2022 | 26,643 | 6,222 | 7,401 | 8,519 | N/A |
| 9/30/2022 | 31,250 | 6,640 | 7,068 | 8,311 | N/A |
| 7/1/2022 | 30,816 | 6,206 | 7,051 | 8,335 | N/A |
| 4/1/2022 | 30,283 | 6,206 | 7,162 | 8,455 | N/A |
| 12/31/2021 | 24,802 | 5,283 | 7,118 | 8,358 | N/A |
| 10/1/2021 | 28,065 | 5,636 | 7,056 | 8,246 | N/A |
| 7/2/2021 | 26,720 | 5,361 | 6,876 | 7,935 | N/A |
| 4/2/2021 | 24,799 | 4,595 | 6,351 | 7,260 | N/A |
| 12/31/2020 | 22,284 | 3,510 | 5,417 | 6,208 | N/A |
| 10/2/2020 | 20,392 | 3,083 | 4,444 | 5,099 | N/A |
| 7/3/2020 | 18,886 | 2,853 | 3,712 | 4,341 | N/A |
| 4/3/2020 | 18,034 | 2,614 | N/A | 4,068 | N/A |
| 12/31/2019 | 17,911 | 2,364 | N/A | 3,952 | N/A |
| 9/27/2019 | 15,562 | 2,093 | N/A | 4,078 | N/A |
| 6/28/2019 | 16,037 | 2,145 | N/A | 4,032 | N/A |
| 3/29/2019 | 16,573 | 2,166 | N/A | 3,896 | N/A |
| 12/31/2018 | 17,049 | 2,406 | N/A | 4,022 | N/A |
| 9/28/2018 | 19,615 | 2,761 | N/A | 3,619 | N/A |
| 6/29/2018 | 19,290 | 2,669 | N/A | 3,772 | N/A |
| 3/30/2018 | 18,819 | 2,553 | N/A | 3,747 | N/A |
| 12/31/2017 | 15,519 | 2,172 | N/A | 3,478 | N/A |
| 9/29/2017 | 17,828 | 2,360 | N/A | 3,292 | N/A |
| 6/30/2017 | 17,432 | 2,191 | N/A | 3,038 | N/A |
| 3/31/2017 | 17,164 | 2,051 | N/A | 3,309 | N/A |
| 12/31/2016 | 16,882 | 2,153 | N/A | 3,522 | N/A |
| 9/30/2016 | 16,621 | 1,927 | N/A | 4,104 | N/A |
| 7/1/2016 | 16,001 | 1,905 | N/A | 4,239 | N/A |
| 4/1/2016 | 13,663 | 1,775 | N/A | 4,051 | N/A |
| 12/31/2015 | 14,434 | 1,747 | N/A | 3,802 | N/A |
| 10/2/2015 | 15,335 | 1,875 | N/A | 3,810 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DHRDas prognostizierte Gewinnwachstum (14.1% pro Jahr) liegt über der Sparquote (3.7%).
Ertrag vs. Markt: DHRDie Erträge des Unternehmens (14.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (17.2% pro Jahr).
Hohe Wachstumserträge: DHRDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: DHRDie Einnahmen des Unternehmens (7.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13.4% pro Jahr).
Hohe Wachstumseinnahmen: DHRDie Einnahmen des Unternehmens (7.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: DHRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/17 04:16 |
| Aktienkurs zum Tagesende | 2026/09/17 00:00 |
| Gewinne | 2026/06/26 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Danaher Corporation wird von 49 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |